Immunomodulators

A compound of formula (I)

• or a pharmaceutically acceptable salt thereof, wherein:
• A is
• wherein:
• denotes the point of attachment to the carbonyl group and denotes the point of attachment to the nitrogen atom;
• z is 0;
• w is 1;
• R14 and R15 are hydrogen;
• and
• Rz is-C(O)NHR16;
• wherein R16 is —CHR17C(O)NH2;
• wherein R17 is selected from hydrogen and —CH2OH;
• Ra, Rc, Re, Rf, Rh, Rj, Rm, and Rn are hydrogen;
• R1 is benzyl optionally substituted with hydroxy;
• R2 is hydrogen or methyl;
• or, Rb and R2, together with the atoms to which they are attached, can form a ring as described below;
• R3 is —CH2C(O)NH2;
• R4 is hydrogen, or, R4 and Rd, together with the atoms to which they are attached, can form a ring as described below;
• R5 is —(CH2)imidazolyl;
• R6 is (CH2)2CO2H;
• R7 is hydrogen or R7 and Rg, together with the atoms to which they are attached, can form a ring as described below;
• R8 is —(CH2)indolyl;
• R9 is —(CH2)2NH2;
• R10 is selected from —(CH2)indolyl and —(CH2)benzothienyl, each optionally substituted with —CH2CO2H;
• R11 is selected from hydrogen, methyl, and butyl;
• R12 is selected from methyl and butyl;
• R13 is isobutyl;
• Rb is selected from C1-C6alkoxyC1-C6alkyl, C1-C6alkyl, carboxyC1-C6alkyl, haloC1-C6alkyl, hydroxyC1-C6alkyl, (NRa′Rb′)C1-C6alkyl wherein Ra′ and Rb′ are independently selected from a hydrogen and C1-C6alkyl, and phenylC1-C6alkyl wherein the phenyl is optionally substituted with one, two, three, four or five groups independently selected from C1-C6alkoxy, C1-C6alkyl, cyano, halo, and nitro;
• or, Rb and R2, together with the atoms to which they are attached, form a ring a selected from azetidine, pyrollidine, morpholine, piperidine, piperazine, and tetrahydrothiazole, wherein each ring is optionally substituted with one to four groups independently selected from amino, cyano, methyl, halo, and hydroxy;
• Rd is selected from hydrogen, C1-C6alkoxyC1-C6alkyl, C1-C6alkyl, carboxyC1-C6alkyl, haloC1-C6alkyl, hydroxyC1-C6alkyl, (NRa′Rb′)C1-C6alkyl wherein Ra′ and Rb′ are independently a selected from hydrogen and C1-C6alkyl, and phenylC1-C6alkyl wherein the phenyl is optionally substituted with one, two, three, four or five groups independently selected from C1-C6alkoxy, C1-C6alkyl, cyano, halo, and nitro;
• or, Rd and R4, together with the atoms to which they are attached, can form a ring selected from azetidine, pyrollidine, morpholine, piperidine, piperazine, and a tetrahydrothiazole, wherein each ring is optionally substituted with one to four groups independently selected from amino, cyano, methyl, halo, hydroxy, and phenyl;
• Rg is selected from hydrogen, C1-C6alkoxyC1-C6alkyl, C1-C6alkyl, carboxyC1-C6alkyl, haloC1-C6alkyl, hydroxyC1-C6alkyl, (NRa′Rb′)C1-C6alkyl wherein Ra′ and Rb′ are independently a selected from hydrogen and C1-C6alkyl, and phenylC1-C6alkyl wherein the phenyl is optionally substituted with one, two, three, four or five groups independently selected from C1-C6alkoxy, C1-C6alkyl, cyano, halo, and nitro;
• or Rg and R7, together with the atoms to which they are attached, can form a ring selected from azetidine, pyrollidine, morpholine, piperidine, piperazine, and a tetrahydrothiazole, wherein each ring is optionally substituted with one to four groups independently selected from amino, cyano, methyl, halo, and hydroxy;
• Rk is selected from C1-C6alkoxyC1-C6alkyl, C1-C6alkyl, carboxyC1-C6alkyl, haloC1-C6alkyl, hydroxyC1-C6alkyl, (NRa′Rb′)C1-C6alkyl wherein Ra′ and Rb′ are independently selected from hydrogen and C1-C6alkyl;
• and phenylC1-C6alkyl;
• and
• R1 is C1-C2alkyl;
• provided that at least one of Rb, Rd, Rg, Rk, and Rl is selected from C1-C6alkoxyC1-C6alkyl, C2-C6alkyl, carboxyC1-C6alkyl, haloC1-C6alkyl, hydroxyC1-C6alkyl, (NRa′Rb′)C1-C6alkyl wherein a Ra′ and Rb′ are independently selected from hydrogen and C1-C6alkyl, and phenylC1-C6alkyl wherein the phenyl is optionally substituted with one, two, three, four or five groups independently selected from C1-C6alkoxy, C1-C6alkyl, cyano, halo, and nitro.